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Insulin-like growth factor-1 receptor expression in pediatric tumors: a comparative
immunohistochemical study
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Background/aim: Insulin-like growth factor-1 receptor (IGF-1R) is a pivotal receptor tyrosine kinase involved in the cell cycle and
malignant tumor transformation. It is differentially expressed in various types of tumors. We aimed to determine the expression of IGF1R in different pediatric tumors and to shed light on possible new indications of anti-IGF-1R treatment approaches.
Materials and methods: A total of 147 specimens were analyzed according to their expression of IGF-1R. Specimens included
those from rhabdomyosarcomas, Wilms tumors, Ewing sarcoma/primitive neuroectodermal tumors, peripheral neuroblastic
tumors, acute lymphoblastic lymphoma, Hodgkin lymphoma, Burkitt lymphoma, retinoblastoma, pleuropulmonary blastoma,
Langerhans cell histiocytosis, endodermal sinus tumors (ESTs), and myeloid sarcoma. Analysis was performed on tissue sections by
immunohistochemically staining for IGF-1R expression.
Results: All six specimens of EST cases showed positivity for IGF-R1. Additionally, about 56% of the Hodgkin lymphoma, 80% of the
rhabdomyosarcoma, and 70% of the Wilms tumor specimens showed positivity for IGF-R1 expression.
Conclusion: All ESTs examined in our study expressed IGF-1R and to our knowledge this is the first report regarding ESTs and IGF-1R
expression. IGF-1R could be included among confirmatory markers for ESTs and, from a therapeutic viewpoint, ESTs should also be
examined for IGF-1R expression for beneficial regimens.
Key words: Insulin-like growth factor-1 receptor, endodermal sinus tumor, neuroblastoma, Wilms tumor, rhabdomyosarcoma

1. Introduction
Insulin-like growth factor-1 receptor (IGF-1R) is a
receptor tyrosine kinase that plays a crucial role in
cancer cell proliferation, migration, and prevention of
apoptosis (1). IGF-1R is also involved in malignant tumor
transformation and is overexpressed in a variety of human
malignancies such as lung, prostate, breast, and colorectal
carcinomas (2–5). Studies have revealed a pronounced
expression of IGF-1R in pediatric tumors, such as Ewing
sarcoma/primitive neuroectodermal tumors (ES/PNETs),
rhabdomyosarcomas (RMSs), osteosarcoma, and synovial
sarcoma (6,7).
Despite the extensive data available for certain tumors,
little is known about the expression of IGF-1R in particular
tumors common to the pediatric population. Additionally,
IGF-1R expression in some tumor types, for example
endodermal sinus tumors (ESTs), has not been reported
in the literature yet and this study is only the third study
* Correspondence: rkarakus@gazi.edu.tr

evaluating IGF-1R expression in Hodgkin lymphoma
(HL). Since anti-IGF-1R monoclonal antibody treatment
is already a part of chemotherapeutic protocols for certain
tumors, it seems worthwhile to identify additional tumor
types that express IGF-1R.
In this study, we investigated the expression of
IGF-1R in different pediatric tumors, including ESTs,
by immunohistochemical analysis. The following
histological specimens were examined: RMSs, Wilms
tumors, ES/PNETs, peripheral neuroblastic tumors
(pNTs, a generic term including neuroblastoma (NB),
ganglioneuroblastoma (GNB), and ganglioneuroma
(GN)), acute lymphoblastic lymphoma (ALL), HL, Burkitt
lymphoma (BL), retinoblastoma (Rb), pleuropulmonary
blastoma (PPB), Langerhans cell histiocytosis (LCH),
ESTs, and myeloid sarcoma (MS). Despite extensive basic
research on IGF-1R, no data on the expression of IGF1R in tissue samples of EST patients have been published
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so far. We aimed to identify additional tumor types that
might express IGF-1R and to shed light on possible new
areas and therapeutic indications of anti-IGF-1R treatment
protocols.
2. Materials and methods
2.1. Tissue specimens
This study included 147 pediatric tumor specimens
sampled from patients diagnosed and/or treated at the
Ankara Children’s Hematology and Oncology Research
and Training Hospital during a 10-year period (2006–
2015). For the use of tissue specimens, informed consent
was obtained from subjects’ parents or guardians and
ethical approval (2014-077) was obtained from the
Ethical Committee of the Ankara Children’s Hematology
and Oncology Research and Training Hospital, Ankara,
Turkey.
2.2. Immunohistochemistry
Immunohistochemical analysis was performed on 4-µmthick, formalin-fixed, paraffin-embedded tissue sections.
Samples were immunohistochemically stained for IGF1R expression. For immunohistochemistry, 3-μm-thick
sections were tested with a Ventana Benchmark GX
immunostainer (Ventana, Tucson, AZ, USA) according to
the instructions of the manufacturer. Diaminobenzidine
was used as a chromogen.
IGF-1R (IGF-1R, Biocare, USA) was used at a dilution of
1:250. A human colon sample was included as the positive

control. For negative controls, primary antibodies were
omitted. Evaluation of IGF-1R staining was performed by
a pathologist without knowledge of the medical history of
the relevant specimen. Immunoreactivity was scored by
determining the percentage of cells showing weak (1+),
moderate (2+), or strong (3+) staining with a cut-off at
10% of cells (2). For all tumors, immunohistochemical
staining frequency patterns were determined.
3. Results
The study group consisted of 147 pediatric tumor
specimens, including 12 RMS, 13 Wilms tumor, eight ES/
PNET, 35 pNT, 11 ALL, 39 HL, 12 BL, one Rb, one PPB,
six LCH, six EST, and three MS samples. The distribution
of several tumors and the staining characteristics of the
tumors for IGF-1R expression are detailed in the Table.
3.1. RMSs
Ten of 12 (83%) RMSs showed positivity for IGF-1R with
membranous, cytoplasmic, and nuclear staining patterns.
Eight of 12 (about 67%) showed moderate to strong
nuclear and membranous staining. Immunoreactivity was
regarded as positive when staining was localized to the
nuclei or cytoplasm. Among the histological parameters,
a higher frequency of nuclear IGF-1R expression was
observed in spindle cell morphology.
3.2. Wilms tumors
Nine of 13 (69%) Wilms tumors were regarded as positive
for IGF-1R in the epithelial component; however, in the

Table. Immunohistochemical staining intensity frequencies for insulin-like growth factor-1 receptor expression in
pediatric tumors.
Staining intensity of IGF-1R
Weak

Moderate

Strong

Overall
staining

Tumor types

Specimen, n

n

%

n

%

n

%

%

EST

6

2

33.3

3

50

1

16.7

100

RMSs

12

2

16.7

5

41.7

3

25

83.3

Wilms tumors

13

4

30.8

5

38.5

0

pNTs

35

7

20

10

28.6

4

11.4

60

HL

39

12

30.8

5

12.8

5

12.8

56.4

ES/PNET

8

1

12.5

2

25

0

Rb

1

0

0

1

PPB

1

0

0

1

69.2

37.5

RMSs = Rhabdomyosarcomas, pNTs = peripheral neuroblastic tumors, HL = Hodgkin lymphoma, Rb =
retinoblastoma, PPB = pleuropulmonary blastoma, EST = endodermal sinus tumor, ES/PNET= Ewing sarcoma/
primitive neuroectodermal tumors. Positivity for IGF-1R is categorized as weak (+1), moderate (+2), and strong (+3).
Percentages are given according to the total number of specimens. For tumor types consisting of single specimens,
percentages are not given.
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3.8. LCH, ALL, BL, and MS
None of the 6 LCH, 11 ALL, 12 BL, or 3 MS samples were
evaluated as positive for IGF-1R expression.

4. Discussion
Increased activation of IGF-IR is known to lead to
dysregulated protein synthesis via certain kinase signaling
pathways, a fact that has already been described for
certain metabolic conditions and for several tumors (8).
The expression pattern of IGF-IR has been investigated for
several tumors but, to our knowledge, the current study
is the first addressing the expression of IGF-1R in ESTs.
To our knowledge, there are also only three studies in
which IGF-1R protein expression was analyzed directly in
tumor tissue of HL patients, as referred to in the following
paragraphs.
It is known that IGF-1R is overexpressed in RMSs,
Wilms tumors, ES/PNETs, and pNTs. However, studies
investigating IGF-1R expression in these groups are rare.
In our study, ten of 12 (83%) specimens tested for IGF-IR
expression stained positive and in spindle cell morphology
a higher frequency of nuclear IGF-1R expression was
observed. A nationwide study comprising 112 cases,
performed by van Gaal et al. in the Netherlands, reported
a slightly lower frequency for IGF-IR expression in RMS
cases (72% for alveolar and 61% for embryonal RMSs) (9).
The slightly higher frequency in our study may be due to
our sample size but still can be regarded in parallel with van
Gaal et al.’s nationwide study. Although we did not perform
clinical correlation or survival analysis, expression of
nuclear IGF-IR has been reported as a negative prognostic
factor for RMS regarding 5-year survival rates (9).
A detailed expression profile of IGF-IR at the genome
and protein level was investigated by Natrajan et al. and it
was reported that IGF-1R protein expression was restricted
to the epithelial cells of fetal kidney and Wilms tumors in
most cases (10). About 70% (nine of 13) of the specimens
investigated in our study showed positivity for IGF-IR

Figure 1. Hodgkin/Reed–Sternberg cells were IGF-1R positive in
the cytoplasm and membrane (magnification 400×).

Figure 2. IGF-1R expression in endodermal sinus tumor tissue
(magnification 100×).

blastemal cells, there was no staining observed. Five of 13
(38%) showed moderate membranous staining.
3.3. ES/PNETs
Three of eight (37%) ES/PNETs showed positivity for IGF1R, all with membranous staining patterns, of which two
showed moderate positivity.
3.4. pNTs
Twenty-one of 35 (60%) pNT specimens were evaluated as
positive for IGF-1R, either membranous with a cytoplasmic
or a nuclear staining pattern. Fourteen of 35 (40%) showed
moderate to strong membranous, cytoplasmic, and nuclear
staining pattern. The frequency of IGF-1R positivity in
GNBs and GNs was significantly higher than in NBs (data
not shown). IGF-1R was mainly stained in ganglion cells
and Schwannian stroma.
3.5. HL
Twenty-two of 39 (56%) HL specimens showed positivity
for IGF-1R with membranous and cytoplasmic staining
patterns. Expression of IGF-1R was observed in the vast
majority of Hodgkin and Reed–Sternberg (HRS) cells
(Figure 1). Ten of 39 (25%) specimens showed moderate
to strong membranous and cytoplasmic staining.
3.6. ESTs
All of the six (100%) EST specimens were evaluated
as positive for IGF-1R, all with membranous staining
patterns. Four of the specimens showed moderate to
strong IGF-1R positivity (Figure 2).
3.7. Rb, PPB
Rb and PPB cases showed positivity for IGF-1R.
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expression in the epithelial component but not perinuclear
localization in blastemal cells. IGF-IR expression in Wilms
tumors has been associated with tumor relapse and is
inversely correlated with the Wilms tumor suppressor gene
(10,11).
In Ewing sarcoma, the aberrant EWS/FLI-1 transcription
factor product has been shown to upregulate the expression
of IGF-1R (12). R1507 is an antibody directed against the
human IGF-1R and the Sarcoma Alliance for Research
through Collaboration conducted a phase two, multiarm
study with this agent in various subtypes of recurrent
or refractory sarcomas including Ewing sarcomas and
concluded that IGF-1R inhibitors could play a role in the
treatment of selected sarcomas (7). Three of eight (37%)
ES/PNET specimens were defined as positive for IGF-1R
in our study. Although studies with IGF-1R antibodies in
ES/PNETs are limited or disappointing, there are assertions
in the literature that IGF-1R inhibitors may play a role in
the treatment of ES/PNETs since it is regarded as a key
mechanism in proliferation (7,12,13).
Neuroblastoma is considered the most common
malignant tumor in the first year of life and IGF-1 signaling
via IGF-1R is thought to contribute to the growth of the
tumor (14). Additionally, IGF-1R is reported as being a major
determinant of the metastatic potential of neuroblastoma
(15). Hence, IGF-1R seems to be a promising therapeutic
target when conventional therapies fail. Sixty percent (21
of 35) of the pNT specimens we evaluated stained positive
for IGF-1R. The antineoplastic therapy of advanced pNTs is
still unsatisfactory and innovative therapeutic approaches
are needed. Anti-IGF-1R therapies are reported to show
beneficial effects in some preclinical studies (15).
HL is one of the most frequent nodal lymphomas and
about 40% of patients are reported to be refractory to initial
treatment or relapse after remission (16). Recently, Eppler
et al. and Liang et al. reported that IGF-1R of variable
frequency is found in cHL patients (16,17). In our study,
about 56% (22 of 39) of the specimens were found to be
expressing IGF-1R, in line with the 55% expression rate
reported by Liang et al. However, in the case of HL, the

expression of IGF-1R with regard to inhibitory options
is somewhat arguable. Liang et al. reported that IGF-1R
is strongly expressed in mitotic cHL cells and inhibition
of IGF-1R decreases proliferation and induces cell-cycle
arrest in cell lines, but in clinical correlation analysis the
expression of IGF-1R was found to be related with better
prognosis (17). Koh et al. recently reported a much lower
expression of IGF-1R (about 14%) in HRS cells and
found a similar prognostic value as reported by Liang et
al. (18). Our study, to our knowledge, is the fourth study
addressing IGF-1R expression in HL cases. In the case
of HL, it is plausible to suggest that studies with larger
samples and using certain antibody clones would clarify
such discrepancies between different studies.
The EST specimens we evaluated in our study showed
100% (6 of 6 specimens) positivity for IGF-1R, all with
membranous staining patterns. Four of them showed
moderate to strong IGF-1R positivity. These findings
suggest a possible role for IGF-1R in ESTs. The current
study is the first to evaluate IGF-1R expression using IHC
on EST specimens. Although histologic characteristics and
frequent AFP expression allow for an accurate diagnosis in
the majority of EST cases, a wide histologic spectrum and
an occasional unexpected immunophenotype may pose
diagnostic challenges. We propose that IGF-1R could be
included among a panel of confirmatory markers for EST.
Our results suggest that IGF-1R may have potential
value as a therapeutic target in pediatric tumors including
RMSs, Wilms tumors, ES/PNET, pNTs, and ESTs. IGF-1R
has a role in malignant transformation and progression;
thus, anti-IGF-1R drugs may be an option for the treatment
of refractory pediatric tumors after validation in future
prospective studies with larger sample size. We report for the
first time that EST expresses IGF-1R, but we are aware that
this result has to be validated with larger sample sizes. Our
results can be enriched by using different antibody clones
for verification and/or by verifying expression patterns also
at the mRNA level. The findings of our study highlight a
potential and possible role of targeting IGF-1R in pediatric
solid tumors by using IGF-1R immunohistochemistry.
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